Haemonetics adds Carlyle operating executive Martin Madaus to board

PUBT · 1d ago
Haemonetics adds Carlyle operating executive Martin Madaus to board
  • Haemonetics elected Martin Madaus to its board, effective July 24, 2026.
  • Madaus is a senior operating executive at Carlyle, advising healthcare investments since 2019.
  • He previously led Ortho Clinical Diagnostics as chairman and CEO, running its turnaround following the Johnson & Johnson carve-out.
  • Earlier roles include chairman, president and CEO of Millipore through its 2010 sale to Merck KGaA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000313143-26-000095), on July 28, 2026, and is solely responsible for the information contained therein.